Business Context and Reporting Period
This Form 8-K is filed by Lineage Cell Therapeutics, Inc. (LCTX) on November 28, 2025. The report addresses a strategic decision regarding a grant application submitted to the California Institute for Regenerative Medicine (CIRM) in June 2025 to support the clinical development of OPC1 for spinal cord injuries (SCI).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a non-financial operational event.
Material Changes
- Grant Application Withdrawal: The Company elected to withdraw its application for a Clinical Trial (CLIN2) award (CIRM Grant) on November 28, 2025.
- Reason for Withdrawal: The decision followed feedback received from CIRM on November 24, 2025. No specific content deficiencies were identified; the withdrawal was a strategic choice to revise the application.
- Resubmission Plan: The Company intends to submit a revised application in the next available CIRM grant cycle, scheduled for January 2026.
Outlook, Management Commentary, and Risks
Management stated that neither the withdrawal of the current application nor the planned resubmission impacts the Company's current and planned development of OPC1. The ongoing DOSED clinical study, which evaluates a novel spinal cord delivery device for administering OPC1 in subacute and chronic SCI participants, will continue as planned. There are no unusual items or new risks disclosed in this filing beyond the temporary delay in potential grant funding.
Investor Verification Checklist
- Verify the timeline for the next CIRM grant application cycle (January 2026).
- Confirm the status and enrollment progress of the ongoing DOSED clinical study.
- Review the Company's cash runway to ensure operations can continue without the anticipated CIRM funding.
- Monitor future filings for the submission of the revised grant application.